ArticleScientific reports2025
Viscous methylene blue formulation for antimicrobial photodynamic therapy in dentistry.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Protonated Defect-Engineered Carbon Nitride Enables Bio-Interface-Enhanced Photodynamic Antibacterial Activity with Potential Periodontal Application.Materials (Basel, Switzerland) · 2026Article
- Effect of Loading Strategy on Methylene Blue Encapsulation in Ethosomes: A Comparative Study of Aqueous and Ethanol Phases.Methods and protocols · 2026Article
- Beta-lactam antibiotics under light: optical and photochemical characterization.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Antimicrobial photodynamic therapy (aPDT) is a promising strategy to combat resistant microbial strains. However, despite its high in vitro efficacy, clinical outcomes often fall short, largely due to insufficient retention of the photosensitizer (PS) at the target site. Factors such as salivary flow and PS aggregation significantly hinder the effectiveness of aPDT. This study presents the development of a high-viscosity methylene blue (MB) formulation tailored for dental aPDT applications. The increased viscosity aims to enhance PS retention at the treatment site, while carefully selected components address MB aggregation, ultimately improving the clinical efficacy of the therapy. Key formulation strategies included the incorporation of a surfactant, anionic polymers, an acidic pH, and reduced MB concentrations to effectively mitigate aggregation. Stability testing demonstrated that the formulation preserved its organoleptic properties, pH, and MB content over 1 year. Although the formulation exhibited lower MB uptake in Candida albicans biofilms compared to aqueous MB, this did not compromise its antimicrobial activity. In vitro aPDT assays showed comparable efficacy between MB in water and the high-viscosity formulation. These findings highlight the potential of the developed viscous MB formulation to enhance the practicality and clinical success of aPDT in dentistry, without compromising its therapeutic effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.